Category: Patent Profiles

    By James DeGiulio — On Apr. 6, 2010, Kylin Therapeutics of West Lafayette, IN announced the issuance of U.S. Patent No. 7,655,787, which broadly covers a number of functionalities for Kylin's lead technology platform, "pRNA," or "packaging RNA."  These functionalities include receptor binding, ribozyme activity, and RNA-interference.  The main feature of pRNA is its…

    By James DeGiulio — On February 9th, Athersys, Inc. was issued U.S. Patent No. 7,659,118 covering multipotent adult stem cells (MASC), their isolation and expansion, and related pharmaceutical compositions.  In a February 10, 2010 press release, the Cleveland-based company also announced the grant of European patent EP 1 218 489 B1, the counterpart to…

    By James DeGiulio — Last week, NexBio, Inc. announced the issuance of U.S. Patent No. 7,645,448, entitled "Class of Therapeutic Protein Based Molecules."  The '448 patent, issued January 12, 2010, is the company's first issued U.S. patent.  The patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®) and methods of treating…

    By James DeGiulio — This week, Fate Therapeutics of San Diego, CA was issued a Notice of Allowance for U.S. Application No. 10/997,146 (U.S. Patent Application Publication No. 2008/0280362), titled "Methods for Reprogramming Somatic Cells."  With a priority date of November 26, 2003, the application is believed to contain the earliest allowed claims in…

    By Sherri Oslick — Last week, Advaxis, Inc., a biotechnology corporation focused on using a bioengineered bacterium, Listeria monocytogenes (Lm), to activate the immune system to treat cancer, infectious disease, or allergic syndromes, was issued U.S. Patent No. 7,588,930 ("Compositions and Methods for Enhancing the Immunogenicity of Antigens").  The '930 patent is directed to…

    By Donald Zuhn — Last month, OncoGenex Pharmaceuticals, Inc. announced that the U.S. Patent and Trademark Office had issued U.S. Patent No. 7,569,551.  The '551 patent is directed to a method of enhancing cancer cell chemo- or radiation-sensitivity using an antisense oligodeoxynucleotide targeted against the testosterone-repressed prostate message-2 (TRPM-2) gene.  The inventors found that…

    By Mark Chael — Recently, Cytori Therapeutics, Inc. announced that the U.S. Patent and Trademark Office had issued a Notice of Allowance for claims directed to prosthetic devices seeded with adipose-derived stem cells.  According to the press release, these claims are related to the use of Cytori's Celution® System for the treatment of bone…

    By Mark Chael — On May 5th, Immunomedics, Inc. announced that its majority-owned subsidiary, IBC Pharmaceuticals, Inc., was granted U.S. Patent No. 7,527,787, entitled "Multivalent Immunoglobulin-based Bioreactive Assemblies."  Claim 1 from the patent reads: 1.  A hexameric stably tethered structure comprising an IgG antibody attached to two AD2 moieties of SEQ ID NO: 4…

    By Mark Chael — On April 29, 2009, ImmunoCellular Therapeutics, Ltd. announced that the U.S. Patent and Trademark Office issued Patent No. 7,498,129, which relates to the company's monoclonal antibody platform.  The '129 patent is entitled "Myeloma Cell and Ovarian Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof," and according to ImmunoCellular, is…

    By Mark Chael — On April 29, 2009, Raptor Pharmaceuticals Corp. announced that the U.S. Patent and Trademark Office recently issued Notices of Allowance for two of its pending patent applications related to methods of delivering drugs to the brain.  The Notices were issued for U.S. Patent Application Nos. 10/812,849 and 11/202,566.  The published…